FDA ends hormone therapy warning, says safe for menopause care

The Food and Drug Administration (FDA) has made a significant decision to reverse a 2003 ruling that imposed strict warnings on hormone therapy products for menopausal women. In a recent statement, Commissioner Marty Makary highlighted the benefits of hormone therapy, specifically mentioning improvements in heart, brain, and bone health.

The FDA is taking steps to remove black box warning labels from various hormone therapy products, including combined estrogen-progestogen, estrogen-only, other estrogen-containing, and progestogen-only treatments. This move aims to provide more nuanced and evidence-based communication regarding the risks and benefits of hormone therapy. The agency is urging companies to update their product labels by eliminating references to cardiovascular, dementia, and breast cancer risks associated with hormone therapy.

The initial impetus for the black box warning stemmed from a landmark 2002 study known as the Women’s Health Initiative, which suggested increased risks of heart disease and breast cancer with hormone therapy. However, subsequent research has shown that hormone therapy can actually benefit menopausal women by improving heart health, reducing insulin resistance, and enhancing cardiovascular biomarkers.

Many clinicians have long advocated for the removal of black box warnings, especially for vaginal products where hormones are not fully absorbed into the bloodstream. A recent expert panel convened by the FDA discussed the risks and benefits of hormone therapies, with a focus on the safety of local estrogen products. Physicians emphasized the relative safety of these drugs, particularly for vaginal use.

While some clinicians support the FDA’s decision to remove the black box warning, concerns have been raised about the lack of a formal advisory committee meeting to review new safety data. The American College of Obstetricians and Gynecologists has recommended a more formal process for evaluating systemic hormone therapies.

Moving forward, hormone therapy products will continue to provide information on adverse events while taking a more tailored approach to each treatment. Updated labels will include specific risks associated with each therapy type, emphasizing the importance of initiating hormone therapy before the age of 60. The FDA will retain a boxed warning for the risk of endometrial cancer when systemic estrogen is used without sufficient progesterone.

Overall, the FDA’s decision to remove black box warnings from hormone therapy products has been met with enthusiasm from healthcare professionals and women’s health advocates. This change aims to provide women with a clearer understanding of the risks and benefits of hormone therapy, allowing for more informed decision-making regarding menopausal symptom management.